Infection is the leading cause of hospital admission and second most common cause of death in patients receiving dialysis
Hemodialysis and peritoneal dialysis (PD) access sites are portals of entry for bacteremia and peritonitis, respectively. Incidence rates of hemodialysis-associated bacteremia and PD peritonitis are 0.42 episodes and 0.3 episodes per patient-year, respectively.1,2 Dialysis confers a 100- to 300-fold higher mortality from sepsis than in the general population.3
Access site–related infections can be localized, systemic, or both
Redness, tenderness, or discharge around access sites suggests infection. However, even if the access site appears normal, patients with sepsis or fever should be investigated, then initiated on antimicrobials.
Staphylococcus species, constituents of skin flora, are the most common bacteria implicated in infections
Empiric methicillin-resistant Staphylococcus aureus (MRSA) coverage is warranted for access site–related infections, as dialysis confers a 100-fold higher risk of developing MRSA infections than in the general population.1
Treatment of hemodialysis access site infections includes antimicrobial therapy and possible line removal or antibiotic lock therapy
Line removal is suggested in persistent (≥ 3 d) bacteremia or when blood cultures are positive for S. aureus, Pseudomonas aeruginosa, or Candida. Systemic antibiotics with adjunctive antibiotic lock therapy (instilling a concentrated solution of antibiotic and anticoagulant to dwell within the catheter lumen when not in use) have a 50% success rate in catheter salvage and may be appropriate even if the access site is the known source of bacteremia.4 Consultation with infectious disease specialists can aid with treatment duration and decisions about line removal and reinsertion as well as surgical arteriovenous graft excision.
Treatment of PD-catheter infections includes antimicrobial therapy and possible catheter removal
Catheter removal is reserved for recurrent or refractory peritonitis, all cases of fungal peritonitis, and localized infections that progress to peritonitis or fail to respond to antibiotics. In PD-catheter peritonitis, intraperitoneal antibiotics with antifungal prophylaxis are preferred over systemic antibiotics unless features of sepsis are present (Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.231300/tab-related-content). Switching to hemodialysis is unnecessary unless the PD catheter is removed.5
CMAJ invites submissions to “Five things to know about …” Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj
Footnotes
Competing interests: None declared.
This article has been peer reviewed.
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
In this issue
Article tools
Jump to section
- Article
- Infection is the leading cause of hospital admission and second most common cause of death in patients receiving dialysis
- Access site–related infections can be localized, systemic, or both
- Staphylococcus species, constituents of skin flora, are the most common bacteria implicated in infections
- Treatment of hemodialysis access site infections includes antimicrobial therapy and possible line removal or antibiotic lock therapy
- Treatment of PD-catheter infections includes antimicrobial therapy and possible catheter removal
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.
More in this TOC Section
Similar Articles
Collections
